Experimental Bladder Cancer Models for Animals

被引:0
|
作者
Kosan, Murat [1 ]
Mungan, Aydin [2 ]
机构
[1] Baskent Univ, Tip Fak, Urol Anabilim Dali, Konya, Turkey
[2] Bulent Ecevit Univ, Tip Fak, Urol Anabilim Dali, Zonguldak, Turkey
来源
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2015年 / 14卷 / 01期
关键词
Bladder cancer; transitional cell carcinoma; experimental animal models;
D O I
10.4274/uob.283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transitional cell carcinoma (TCC) is the most common malignancy of the genitourinary tract and TCC models are being developed over the past decades. Experimental models are needed so that more effective treatments can be developed in preclinical evaluation. Even if, in vitro models are useful for initial development and evaluation of therapeutic agents and modalities, adequate animal models are still essential in the preclinical development of new effective and safe therapies. A great variety of ex vivo and in vivo models has been described in the literature. Chemical carcinogens are most commonly used to induce bladder cancer. Cell culture techniques are also widely used to study different oncological processes. To test potential new drugs in a preclinical setting, a clinically relevant orthotopic bladder tumor model is highly desirable. The aim of this review article was the assessment of different animal models available for the study of bladder carcinogenesis.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [31] Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer
    Desponds, Emma
    Kioseoglou, Konstantina
    Zdimerova, Hana
    Ongaro, Marco
    Verdeil, Gregory
    Leblond, Marine M.
    CANCERS, 2024, 16 (12)
  • [32] Current Preclinical Models for the Advancement of Translational Bladder Cancer Research
    DeGraff, David J.
    Robinson, Victoria L.
    Shah, Jay B.
    Brandt, William D.
    Sonpavde, Guru
    Kang, Yibin
    Liebert, Monica
    Wu, Xue-Ru
    Taylor, John A., III
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) : 121 - 130
  • [33] Tree models for dependent copy number changes in bladder cancer
    Schäffer, AA
    Simon, R
    Desper, R
    Richter, J
    Sauter, G
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (02) : 349 - 354
  • [34] Analysis of bladder cancer subtypes in neurogenic bladder tumors
    Manach, Quentin
    Cussenot, Olivier
    Roupret, Morgan
    Game, Xavier
    Chartier-Kastler, Emmanuel
    Reus, Christine
    Camparo, Philippe
    Comperat, Eva
    Phe, Veronique
    CANADIAN JOURNAL OF UROLOGY, 2018, 25 (01) : 9161 - 9167
  • [35] Bladder preservation in invasive locally confined bladder cancer
    Jung, P
    Jakse, G
    ONKOLOGIE, 1996, 19 (04): : 296 - 301
  • [36] Elective bladder preservation with multimodality treatment for bladder cancer
    Mayadagli, A.
    Kocak, M.
    Demir, O.
    Gul, S. Karabulut
    Ozkan, A.
    Parlak, C.
    Yaprak, G.
    Gumus, M.
    JOURNAL OF BUON, 2012, 17 (03): : 483 - 489
  • [37] SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
    Merseburger, Axel S.
    Apolo, Andrea B.
    Chowdhury, Simon
    Hahn, Noah M.
    Galsky, Matthew D.
    Milowsky, Matthew I.
    Petrylak, Daniel
    Powles, Tom
    Quinn, David I.
    Rosenberg, Jonathan E.
    Siefker-Radtke, Arlene
    Sonpavde, Guru
    Sternberg, Cora N.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (01) : 95 - 105
  • [38] New agents for bladder cancer
    Bellmunt, J.
    Guix, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 56 - 58
  • [39] Docetaxel for the treatment of bladder cancer
    Albany, Costantine
    Sonpavde, Guru
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (12) : 1657 - 1664
  • [40] Bladder cancer radiotherapy margins
    Regnier, E.
    Nguyen, T. D.
    Beckendorf, V.
    Lagrange, J. -L.
    CANCER RADIOTHERAPIE, 2013, 17 (5-6): : 470 - 476